Biomarker testing will play a key role in moving precision medicine forward in 2024, says Lyn Fitzgerald, Ontada's VP Sales Oncology Data, Evidence & Insights. Precise RWD insights will be pivotal in identifying and testing the right patients at the right time. Watch the full interview.
